Quest Diagnostics Inc. vs. Veracyte, Inc.
Quest Diagnostics Inc. (DGX) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| DGX | VCYT | |
|---|---|---|
| Market Cap | $26.23 billion | $3.70 billion |
| Revenue (TTM) | $11.56 billion | $561.90 million |
| Net Income (TTM) | $1.11 billion | $114.48 million |
DGX leads on 3 of 3 size & scale factors.
Valuation
| DGX | VCYT | |
|---|---|---|
| P/E Ratio | 24.63 | 31.56 |
| Price / Book | 3.35 | 2.67 |
| Price / Sales | 2.27 | 6.59 |
DGX leads on 2 of 3 valuation factors.
Profitability
| DGX | VCYT | |
|---|---|---|
| Net Margin | 9.63% | 20.37% |
| Return on Equity | 14.23% | 8.25% |
DGX and VCYT split the profitability factors evenly.
Dividend
| DGX | VCYT | |
|---|---|---|
| Dividend Yield | 1.48% | — |
| Payout Ratio | 36.52 | — |
DGX and VCYT split the dividend factors evenly.
Risk & Sentiment
| DGX | VCYT | |
|---|---|---|
| Short Interest | 4.76% | 0.83% |
VCYT leads on 1 of 1 risk & sentiment factors.
Dig deeper: DGX overview, DGX financials, VCYT overview, VCYT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.